191 related articles for article (PubMed ID: 37883186)
21. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
22. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
23. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
25. Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports.
Xu J; Ming X; Wang C; Xu B; Xiao Y
Medicine (Baltimore); 2021 May; 100(18):e25784. PubMed ID: 33950974
[TBL] [Abstract][Full Text] [Related]
26. B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.
Gagelmann N; Ayuk F; Atanackovic D; Kröger N
Eur J Haematol; 2020 Apr; 104(4):318-327. PubMed ID: 31883150
[TBL] [Abstract][Full Text] [Related]
27. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
Sun F; Cheng Y; Wanchai V; Guo W; Mery D; Xu H; Gai D; Siegel E; Bailey C; Ashby C; Al Hadidi S; Schinke C; Thanendrarajan S; Ma Y; Yi Q; Orlowski RZ; Zangari M; van Rhee F; Janz S; Bishop G; Tricot G; Shaughnessy JD; Zhan F
Nat Commun; 2024 Jan; 15(1):615. PubMed ID: 38242888
[TBL] [Abstract][Full Text] [Related]
28. SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions.
Biltibo E; Berdeja JG
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):310-321. PubMed ID: 36925390
[TBL] [Abstract][Full Text] [Related]
29. Directed targeting of B-cell maturation antigen-specific CAR T cells by bioinformatic approaches: From in-silico to in-vitro.
Moazzeni A; Kheirandish M; Khamisipour G; Rahbarizadeh F
Immunobiology; 2023 May; 228(3):152376. PubMed ID: 37058845
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Deng H; Liu M; Yuan T; Zhang H; Cui R; Li J; Yuan J; Wang X; Wang Y; Deng Q
Front Immunol; 2021; 12():720571. PubMed ID: 34421924
[TBL] [Abstract][Full Text] [Related]
31. Vγ9Vδ2 T cells expressing a BCMA-Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth.
Zhang X; Ng YY; Du Z; Li Z; Chen C; Xiao L; Chng WJ; Wang S
PLoS One; 2022; 17(6):e0267475. PubMed ID: 35709135
[TBL] [Abstract][Full Text] [Related]
32. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.
Duan D; Wang K; Wei C; Feng D; Liu Y; He Q; Xu X; Wang C; Zhao S; Lv L; Long J; Lin D; Zhao A; Fang B; Jiang J; Tang S; Gao J
Front Immunol; 2021; 12():609421. PubMed ID: 33767695
[TBL] [Abstract][Full Text] [Related]
33. Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization.
Camviel N; Wolf B; Croce G; Gfeller D; Zoete V; Arber C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323436
[TBL] [Abstract][Full Text] [Related]
34. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.
Que Y; Xu M; Xu Y; Almeida VDF; Zhu L; Wang Z; Wang Y; Liu X; Jiang L; Wang D; Li C; Zhou J
Front Immunol; 2021; 12():755866. PubMed ID: 34777368
[TBL] [Abstract][Full Text] [Related]
35. Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T.
Singh AP; Chen W; Zheng X; Mody H; Carpenter TJ; Zong A; Heald DL
CPT Pharmacometrics Syst Pharmacol; 2021 Apr; 10(4):362-376. PubMed ID: 33565700
[TBL] [Abstract][Full Text] [Related]
36. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity.
Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z
Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.
Jiang D; Huang H; Qin H; Tang K; Shi X; Zhu T; Gao Y; Zhang Y; Tian X; Fu J; Qu W; Cai W; Xu Y; Wu D; Chu J
Nat Commun; 2023 Jun; 14(1):3642. PubMed ID: 37339964
[TBL] [Abstract][Full Text] [Related]
39. BCMA CAR T cells: the winding path to success.
Borrello I; Imus PH
J Clin Invest; 2019 Apr; 129(6):2175-2177. PubMed ID: 31033482
[TBL] [Abstract][Full Text] [Related]
40. Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
Buonato JM; Edwards JP; Zaritskaya L; Witter AR; Gupta A; LaFleur DW; Tice DA; Richman LK; Hilbert DM
Mol Cancer Ther; 2022 Jul; 21(7):1171-1183. PubMed ID: 35737298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
